| Cardiovascular and renal outcomes with empagliflozin in heart failure M Packer, SD Anker, J Butler, G Filippatos, SJ Pocock, P Carson, ... New England Journal of Medicine 383 (15), 1413-1424, 2020 | 3816 | 2020 |
| Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European … BA Ference, HN Ginsberg, I Graham, KK Ray, CJ Packard, E Bruckert, ... European heart journal 38 (32), 2459-2472, 2017 | 3221 | 2017 |
| Effect of very high-intensity statin therapy on regression of coronary atherosclerosis: the ASTEROID trial SE Nissen, SJ Nicholls, I Sipahi, P Libby, JS Raichlen, CM Ballantyne, ... Jama 295 (13), 1556-1565, 2006 | 3002 | 2006 |
| Empagliflozin in heart failure with a preserved ejection fraction SD Anker, J Butler, G Filippatos, JP Ferreira, E Bocchi, M Böhm, ... New England Journal of Medicine 385 (16), 1451-1461, 2021 | 2849 | 2021 |
| Effects of dalcetrapib in patients with a recent acute coronary syndrome GG Schwartz, AG Olsson, M Abt, CM Ballantyne, PJ Barter, J Brumm, ... New England Journal of Medicine 367 (22), 2089-2099, 2012 | 2256 | 2012 |
| Antiinflammatory properties of HDL PJ Barter, S Nicholls, KA Rye, GM Anantharamaiah, M Navab, ... Circulation research 95 (8), 764-772, 2004 | 1687 | 2004 |
| Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus: a meta-analysis of randomized trials AM Lincoff, K Wolski, SJ Nicholls, SE Nissen Jama 298 (10), 1180-1188, 2007 | 1653 | 2007 |
| Effects of fibrates on cardiovascular outcomes: a systematic review and meta-analysis M Jun, C Foote, J Lv, B Neal, A Patel, SJ Nicholls, DE Grobbee, A Cass, ... The Lancet 375 (9729), 1875-1884, 2010 | 1192 | 2010 |
| Effect of torcetrapib on the progression of coronary atherosclerosis SE Nissen, JC Tardif, SJ Nicholls, JH Revkin, CL Shear, WT Duggan, ... New England Journal of Medicine 356 (13), 1304-1316, 2007 | 1159 | 2007 |
| Effect of two intensive statin regimens on progression of coronary disease SJ Nicholls, CM Ballantyne, PJ Barter, MJ Chapman, RM Erbel, P Libby, ... New England Journal of Medicine 365 (22), 2078-2087, 2011 | 1104 | 2011 |
| Effect of evolocumab on progression of coronary disease in statin-treated patients: the GLAGOV randomized clinical trial SJ Nicholls, R Puri, T Anderson, CM Ballantyne, L Cho, JJP Kastelein, ... Jama 316 (22), 2373-2384, 2016 | 1090 | 2016 |
| Low-density lipoproteins cause atherosclerotic cardiovascular disease: pathophysiological, genetic, and therapeutic insights: a consensus statement from the European … J Boren, MJ Chapman, RM Krauss, CJ Packard, JF Bentzon, CJ Binder, ... European heart journal 41 (24), 2313-2330, 2020 | 1049 | 2020 |
| Comparison of pioglitazone vs glimepiride on progression of coronary atherosclerosis in patients with type 2 diabetes: the PERISCOPE randomized controlled trial SE Nissen, SJ Nicholls, K Wolski, R Nesto, S Kupfer, A Perez, H Jure, ... Jama 299 (13), 1561-1573, 2008 | 1007 | 2008 |
| Statins, high-density lipoprotein cholesterol, and regression of coronary atherosclerosis SJ Nicholls, EM Tuzcu, I Sipahi, AW Grasso, P Schoenhagen, T Hu, ... Jama 297 (5), 499-508, 2007 | 975 | 2007 |
| Myeloperoxidase and cardiovascular disease SJ Nicholls, SL Hazen Arteriosclerosis, thrombosis, and vascular biology 25 (6), 1102-1111, 2005 | 961 | 2005 |
| Protein carbamylation links inflammation, smoking, uremia and atherogenesis Z Wang, SJ Nicholls, ER Rodriguez, O Kummu, S Hörkkö, J Barnard, ... Nature medicine 13 (10), 1176-1184, 2007 | 783 | 2007 |
| Evacetrapib and cardiovascular outcomes in high-risk vascular disease AM Lincoff, SJ Nicholls, JS Riesmeyer, PJ Barter, HB Brewer, KAA Fox, ... New England Journal of Medicine 376 (20), 1933-1942, 2017 | 727 | 2017 |
| Effect of high-dose omega-3 fatty acids vs corn oil on major adverse cardiovascular events in patients at high cardiovascular risk: the STRENGTH randomized clinical trial SJ Nicholls, AM Lincoff, M Garcia, D Bash, CM Ballantyne, PJ Barter, ... Jama 324 (22), 2268-2280, 2020 | 668 | 2020 |
| Relationship of paraoxonase 1 (PON1) gene polymorphisms and functional activity with systemic oxidative stress and cardiovascular risk T Bhattacharyya, SJ Nicholls, EJ Topol, R Zhang, X Yang, D Schmitt, X Fu, ... Jama 299 (11), 1265-1276, 2008 | 648 | 2008 |
| Association of triglyceride-lowering LPL variants and LDL-C–lowering LDLR variants with risk of coronary heart disease BA Ference, JJP Kastelein, KK Ray, HN Ginsberg, MJ Chapman, ... Jama 321 (4), 364-373, 2019 | 583 | 2019 |
Rishi PuriCardiovascular Medicine, Cleveland ClinicVerified email at ccf.org
